Electronic Resource
Lenalidomide in multiple myeloma: Current status and future potential.
| العنوان: | Lenalidomide in multiple myeloma: Current status and future potential. |
|---|---|
| المؤلفون: | Quach H., Spencer A., Kalff A. |
| بيانات النشر: | Wiley-Liss Inc. (111 River Street, Hoboken NJ 07030-5774, United States) United States 2012-11-27 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | The clinical development of lenalidomide (RevlimidTM), then pomalidomide (ActimidTM) as members of immunomodulatory drugs (IMiDs) for the treatment of multiple myeloma (MM), exemplifies how insight into disease biology can lead to design of effective therapeutic agents. Increased experience and understanding of IMiD's diverse biological effects has lead to rational design of lenalidomide-based treatment-regimens over recent years. However, much about lenalidomide is yet to be understood and fully exploited. Here, we review what is known of lenalidomide's biological effects, clinical certainties and uncertainties in the treatment of MM, and explore its future potential with other synergistic therapeutic agents. © 2012 Wiley Periodicals, Inc. |
| مصطلحات الفهرس: | stroma cell, autologous stem cell transplantation, cancer recurrence, cell cycle arrest, cytogenetics, drug efficacy, drug megadose, drug potentiation, drug safety, human, immunity, immunomodulation, infection/si [Side Effect], multiple myeloma/dt [Drug Therapy], multiple myeloma/di [Diagnosis], multiple myeloma/th [Therapy], neutropenia/si [Side Effect], phase 3 clinical trial (topic), priority journal, randomized controlled trial (topic), review, apoptosis, thrombocytopenia/si [Side Effect], treatment duration, treatment response, venous thromboembolism/si [Side Effect], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/it [Drug Interaction], dexamethasone/dt [Drug Therapy], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/it [Drug Interaction], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pd [Pharmacology], melphalan/ct [Clinical Trial], melphalan/cb [Drug Combination], melphalan/dt [Drug Therapy], pomalidomide/dt [Drug Therapy], prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], prednisone/dt [Drug Therapy], thalidomide/dt [Drug Therapy], antineoplastic activity, Review |
| URL: | Click here for full text options LibKey Link |
| الاتاحة: | Open access content. Open access content Copyright 2013 Elsevier B.V., All rights reserved. |
| Other Numbers: | AUSHL oai:repository.monashhealth.org:1/28291 American Journal of Hematology. 87 (12) (pp 1089-1095), 2012. Date of Publication: December 2012. 0361-8609 https://repository.monashhealth.org/monashhealthjspui/handle/1/28291 22641420 [http://www.ncbi.nlm.nih.gov/pubmed/?term=22641420] 52035313 (Quach, Kalff, Spencer) Myeloma Research Group, Australian Centre for Blood Diseases, Monash University, Clayton, VIC, Australia (Quach) Department of Clinical Haematology, Monash Medical Centre, Clayton, VIC, Australia (Quach, Spencer) Department of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia (Kalff, Spencer) Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia Quach H.; hang.quach@monash.edu 1305135751 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1305135751 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |